Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A. Mato AR, et al. Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25691474 Free article. Clinical Trial.
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ. Mato AR, et al. Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873. Epub 2015 Dec 23. Blood. 2016. PMID: 26702066 Free article. No abstract available.
Ibrutinib for Chronic Lymphocytic Leukemia.
Sharman JP, Mato AR, Keating MJ. Sharman JP, et al. Among authors: mato ar. N Engl J Med. 2016 Apr 21;374(16):1592-3. doi: 10.1056/NEJMc1600328. N Engl J Med. 2016. PMID: 27096595 No abstract available.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Mato AR, et al. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977. Epub 2016 Sep 6. Blood. 2016. PMID: 27601462 Free article.
Emerging Strategies in Treating Double Hit Lymphomas.
Nabhan C, Mato AR. Nabhan C, et al. Among authors: mato ar. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):563-568. doi: 10.1016/j.clml.2017.06.017. Epub 2017 Jun 21. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28711572 Review.
Biosimilars in Oncology in the United States: A Review.
Nabhan C, Parsad S, Mato AR, Feinberg BA. Nabhan C, et al. Among authors: mato ar. JAMA Oncol. 2018 Feb 1;4(2):241-247. doi: 10.1001/jamaoncol.2017.2004. JAMA Oncol. 2018. PMID: 28727871 Review.
122 results